Edition:
United Kingdom

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

56.50USD
16 Feb 2018
Change (% chg)

$0.05 (+0.09%)
Prev Close
$56.45
Open
$56.20
Day's High
$57.15
Day's Low
$55.90
Volume
101,392
Avg. Vol
194,788
52-wk High
$63.00
52-wk Low
$22.80

Chart for

About

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.... (more)

Overall

Beta: --
Market Cap(Mil.): $4,359.11
Shares Outstanding(Mil.): 78.97
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Fibrogen Inc reports Q3 loss per share $0.50

* Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S

08 Nov 2017

BRIEF-Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease

* Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD)

18 Oct 2017

BRIEF-Fibrogen's ‍Pamrevlumab was well tolerated with no safety risks

* ‍Announced results from co's phase 2b randomized, double-blind, placebo-controlled study in patients with idiopathic pulmonary fibrosis​

13 Sep 2017

Earnings vs. Estimates